Stereotactic Radiation Therapy for Pediatric Sarcomas

Completed · Not applicable

Conditions studied: Sarcoma, Metastatic Disease, Bony Sites

In brief

The stereotactic body radiation therapy (SBRT) literature focuses on clinical outcomes in the adult population. However, SBRT has a particularly strong rationale for application in pediatrics given that high biologically effective doses have been shown to increase control in histologies, such as sarcoma, which are common in the pediatrics population. With stereotactic radiation therapy techniques, a reduction in normal tissue dose surrounding the target lesion of interest may also be accomplished resulting in lower toxicity. Given that pediatric patients with sarcomas, presenting with limited metastases in lung and bone, are still considered to be a curable population with aggressive local therapy, SBRT could have a significant impact on outcomes in oligometastatic patients who may be otherwise unresectable.

Key facts

Study ID

NCT01763970

Run by

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

People needed

14

Starts

2013-11-01

Expected to finish

2020-04-01

Last updated by the study team

2020-08-27

Who can join

Age: 4 and older, up to 40. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• histologically or cytologically confirmed metastatic sarcoma of the soft tissue or bone
• must have measurable disease
• disease must be surgically unresectable as determined by a tumor board or surgeon
• greater than 3 years of age
• less than or equal to 40 years of age
• life expectancy of at least 9 months
• adequate performance status (Lansky Performance Status greater than or equal to 50).
• ability to understand and willingness to sign informed consent document

You may not qualify if…

• patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study
• patients who have had any prior radiotherapy to the treatment site(s)
• patients may not participate on any other treatment protocol while they are receiving treatment on this protocol and for up to 3 months after these protocol treatments have ended
• pregnant women
• refusal of women of child bearing potential to take a pregnancy test prior to treatment

Where it is running

• Stanford Medical Center — Stanford, California, United States
• Sibley Memorial Hospital — Washington D.C., District of Columbia, United States
• The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
• Mayo Clinic — Rochester, Minnesota, United States
• St. Jude Children's Research Hospital — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.